A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

To be considered for this study, you would need to have non-small cell lung cancer that has spread and cannot be cured by surgery or radiation. Your cancer must also have a specific genetic change called KRAS G12C. This study is for people who haven't had other treatments for their advanced lung cancer already, although in some urgent cases, one cycle of initial treatment might be allowed.

Important factors include being generally well enough to participate, with a good estimated life expectancy of at least 12 weeks, and the ability to swallow capsules. Your doctor will check your overall health and various blood tests to make sure you can safely take part. For women who could become pregnant, a negative pregnancy test is needed, and you must not be breastfeeding during the study.

You would not be able to join if your cancer has other specific genetic changes that doctors already know how to treat, such as EGFR or ALK mutations. Also, if you have active cancer in your brain or the lining around your brain, you wouldn't be able to participate. This study is generally for people aged 18 and over, of any sex.

If you decide to participate, the study could last up to three years. This isn't a fixed time, but rather depends on how you are feeling and how your lung cancer is responding to treatment. You would receive one of the study drugs – olomorasib, pembrolizumab, or a placebo (a dummy pill) – possibly along with chemotherapy, according to a plan decided by the study doctors.

Throughout the study, you would have regular visits to the clinic for medical checks, blood tests, and scans. These assessments help the doctors monitor your health, how the treatment is working, and if you are experiencing any side effects. You can always decide to stop taking part in the study at any time, for any reason, without it affecting your usual medical care.